Ovid Therapeutics

Ovid Therapeutics initiates phase I trial of OV101 for Angelman or Fragile X syndrome

Wednesday, April 12, 2017

Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, has initiated a phase I clinical trial to evaluate the pharmacokinetics (PK), safety and tolerability of OV101 in adolescents diagnosed with Angelman syndrome or Fragile X syndrome. OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, is believed to be the first investigational drug to target the disruption of tonic inhibition, a key mechanism that allows a healthy human brain to decipher excitatory and inhibitory neurological signals correctly without being overloaded. Tonic inhibition is believed to play a significant role in the neurodevelopmental symptoms characteristic of disorders such as Angelman syndrome and Fragile X syndrome.

[Read More]

Takeda, Ovid Therapeutics partner on rare pediatric epilepsies

Friday, January 20, 2017

Takeda Pharmaceutical and Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, have announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully completed several phase I clinical studies under Takeda’s leadership and will be moving into phase Ib/IIa clinical studies in rare epileptic encephalopathies where patients continue to suffer from significant unmet medical needs.

[Read More]

Boston hosts Biopharm America

Tuesday, September 15, 2015

Biopharm America, which is designed to spur strategic relationships by way of a Web-based service that sets up face-to-face meetings and more, kicks off today in Boston with more than 450 companies, 680 delegates and 770 licensing opportunities on the roster.

[Read More]